Renaissance Capital logo

Actuate Therapeutics Scheduled, Nasdaq: ACTU

Phase 2 biotech developing an inhibitor therapy for difficult to treat cancers.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3ß signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). The lead drug in our portfolio is called elraglusib (9-ING-41), which is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, our most advanced clinical indication to date. Elraglusib represents a broad opportunity for us to potentially initiate and advance multiple drug development programs around our lead asset based on data emerging from completed or ongoing Phase 1/2 trials in pediatric and adult patients with advanced, refractory cancers.
more less
IPO Data
IPO File Date 05/24/2024
Offer Price
Price Range $8.00 - $10.00
Offer Shares (mm) 5.6
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $8.00 - $10.00
Offer Shares (mm) 5.6
Deal Size ($mm) $50
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Titan Partners
Newbridge Securities
Company Data
Headquarters Fort Worth, TX, United States
Founded 2015
Employees 15
Website www.actuatetherapeutics.com

Actuate Therapeutics (ACTU) Performance